AI and the Future of Pharma with Bob Bradway, CEO of Amgen

Why It Matters

Amgen’s company‑wide AI integration accelerates drug discovery and reduces costs, giving it a strategic advantage in a rapidly evolving biotech landscape.

Key Takeaways

• Early AI investment leveraged Icelandic genetic database for target discovery.
• AI-driven protein folding models accelerate molecule selection, cutting development time.
• End‑to‑end AI integration spans R&D, manufacturing, and commercial functions.
• Change‑management framework built during 2013 patent crunch now drives AI adoption.
• Quantum‑computing research prepares Amgen for next‑generation molecular simulations.

Summary

Bob Bradway, Amgen’s long‑time CEO, discussed how the company has woven artificial intelligence into every stage of drug development, from early target discovery to commercial launch. Amgen’s first AI‑focused move was the 2012 acquisition of Decode, a Icelandic genetics repository, paired with the belief that emerging AI tools would eventually make sense of its massive, longitudinal data set.

Bradway highlighted how advances such as DeepMind’s AlphaFold and Amgen’s own NVIDIA super‑pod have transformed protein‑folding predictions, slashing the time needed to select promising molecules and reducing costly late‑stage failures. The firm now applies AI to visual inspection in manufacturing, capacity modeling, and emerging sales‑enablement tools, treating the technology as a cross‑functional accelerator rather than an R&D silo.

A recurring theme was the importance of change‑management. In 2013, facing patent expirations, Amgen overhauled its organization, creating a leadership cadre that now shepherds AI adoption. Bradway also flagged quantum‑computing research as a forward‑looking hedge, exploring how quantum algorithms could model protein dynamics beyond classical limits.

The interview underscores that Amgen’s early, holistic AI strategy is delivering faster molecule selection, lower development risk, and a competitive edge across the value chain, positioning the company to capitalize on next‑generation computational breakthroughs.

Original Description

How do you get ahead, when all of your competitors have access to the same revolutionary AI tools? According to Bob Bradway, CEO of Amgen, it’s by getting a head start.

Bob Bradway started his digital transformation at Amgen when he took the helm 14 years ago. Today, driven by AI, they’re transforming every step of their business with forward-thinking and discretion. And looking ahead at agentic innovations, he’s getting his hands on the keyboard to lead from the top.

Hear how AI is transforming not just how new drugs are developed, but how the people behind the drugs work and think.

Join the Conversation: To learn more about the Winning with AI podcast check out (https://www.bain.com/insights/topics/winning-with-ai-podcast/) or hit the link for additional AI Insights (https://www.bain.com/insights/topics/ai/)

Bain & Company LinkedIn | / bain-and-company

Bain & Company X | https://x.com/BainandCompany